



# Biotech Daily

Friday January 28, 2011

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH DOWN: SUNSHINE, TISSUE UP 13%; CELLMID DOWN 6%**
- \* **GENETIC TECHNOLOGIES H1 \$4.3m MAIDEN PROFIT; REVENUE UP 184%**
- \* **RESMED RECORD QUARTER, H1 REVENUE, PROFIT**
- \* **IMPEDIMED SHARE PLAN RAISES \$4.3m OF HOPED FOR \$5m**
- \* **BLUECHIIP LAUNCHES NEW TRACKING READER IN PALM SPRINGS**
- \* **BONE HAS \$3.4k CASH; \$6m CONVERTIBLE NOTE**
- \* **NESTOR TAKES 5.4% OF GENERA**
- \* **MAYNE APPOINTS ROGER CORBETT CHAIRMAN**
- \* **CLINUVEL HOSTS SWISS PHOTO-DERMATOLOGY MEETING**

## MARKET REPORT

The Australian stock market fell 0.65 percent on Friday January 28, 2011 with the S&P ASX 200 down 31.2 points to 4774.9 points.

Ten of the Biotech Daily Top 40 stocks were up, 13 fell, 10 traded unchanged and seven were untraded.

Sunshine Heart and Tissue Therapies were the best, both up 13.3 percent to 3.4 cents and 64 cents, respectively, with 1.3 million and 460,091 shares traded, respectively.

LBT climbed 9.3 percent; Cathrx, Genetic Technologies, Phylogica and Prima were up four percent or more; Prana was up 3.7 percent; with Acrux and QRX up more than two percent.

Cellmid led the falls, down 0.2 cents or 5.7 percent to 3.3 cents with 2.5 million shares traded.

Circadian and Living Cell lost more than three percent; Bionomics, Patrys and Viralytics shed more than two percent; with CSL, Heartware, Impedimed, Pharmaxis, Resmed and Starpharma down more than one percent.

## GENETIC TECHNOLOGIES

Genetic Technologies has claimed an unaudited half-year maiden profit of \$4.3 million for the six months to December 31, 2010.

Genetic Technologies said total revenue for the six months of \$14,219,032 was up 184.3 percent compared to the previous corresponding period of \$5,000,694.

The company said it received \$10,807,177 in the three months to December 31, 2010.

Genetic Technologies said the revenue "was due largely to receipts from a number of new non-coding licences granted ... to parties including Innogenetics, Pioneer Hi-Bred International and Qiagen, together with a solid performance from the company's genetic testing operations".

Genetic Technologies said it had a program of ongoing cost reductions and at December 31, 2010, the company had \$8.4 million in cash.

The company said licencing operations were unpredictable and the timing and quantum of revenues were irregular.

Genetic Technologies said that as new patent infringements suits were filed, there were potentially months of negotiations before settlements were reached and fees received.

"There can be no guarantee that the large increase in revenues during the first half of the 2011 financial year will be repeated in the remainder of the year, or that a profit will be generated for the full financial year ending June 30, 2011," the company said.

Genetic Technologies was up half a cent or 4.35 percent to 12 cents with 1.2 million shares traded.

## RESMED

Resmed has posted record revenue of \$US588.0 million up 12.6 percent and profit up 30.8 percent to \$US115.2 million for the six months to December 31, 2010.

Resmed said diluted earnings per share was 73 US cents, a 28 percent increase over the six months ended December 31, 2009.

The company said revenue for the three months to December 31, 2010 quarter was up 11 percent to \$US306.1 million compared to the quarter to December 31, 2009, with net profit after tax up 27 percent to \$US58.5 million.

Resmed said research and development expenditure for the quarter was \$22.0 million, or seven percent of revenue.

Resmed fell five cents or 1.5 percent to \$3.19 with 12.7 million shares traded.

## IMPEDIMED

Impedimed says it has raised \$4.27 million through its share purchase plan at 70 cents a share.

In December 2010, Impedimed raised \$10 million through the placement of 14.3 million shares to support the roll-out of its L-Dex lymphoedema diagnostic in the US and secure reimbursement coverage from US healthcare insurers (BD: Dec 3, 2010).

The company said all valid share plan applications had been accepted in full.

Impedimed said the plan was underwritten by underwriters Wilson HTM and RBS Morgans to a maximum of \$4.27 million and accordingly no shares would be placed with the underwriters.

Impedimed fell 1.5 cents or 1.9 percent to 78.5 cents.

### BLUECHIIP

Bluechiip will launch a prototype of a new reader for its medical tracking technology at Lab Automation 2011 in Palm Springs, California from January 30 to February 1, 2011.

Bluechiip hopes to list on the ASX with an initial public offer of 24,000,000 shares at 25 cents each to raise \$6 million to complete development and commercial production.

The offer closes on February 28, 2011 (BD: Nov 12, 2010).

Bluechiip said its tracking technology had several applications, with the initial market in bio-banking "due to the pressing need for improved tracking, identification and monitoring".

The company said it would demonstrate the prototype of the integrated reader which could be used for tubes, vials, bags and other sample storage containers, as well as carriers such as racks and when coupled with the Bluechiip tag, would "see tracking and retrieval of high value samples in bio-banks and bio-repositories taken to a level yet to be seen in the market".

### BONE MEDICAL

Bone said its net operating cash burn for the three months to December 31, 2010 was \$116,703 with cash at the end of the quarter of \$3,359.

Last year, Bone announced that it had a \$6 million convertible note equity draw down facility with La Jolla Cove (BD: Sep 14, 2010).

Bone was untraded at 4.3 cents.

### GENERA BIOSYSTEMS

Nestor Investment Management has become a substantial shareholder in Genera with the acquisition of 3,378,507 shares or 5.39 percent of the company.

The initial substantial shareholder notice from the Grand Duchy of Luxembourg said Nestor Investment Management acquired the shares for Nestor Australien Fonds and the most recent purchase was 50,000 shares for \$20,051 or 40.1 cents a share on November 17, 2010.

Genera was untraded at 49 cents.

### MAYNE PHARMA (FORMERLY HALCYGEN)

Mayne has appointed former Woolworths chief executive officer Roger Corbett as its chairman.

Mayne said Mr Corbett had "unparalleled retail and corporate experience".

The company said Mr Corbett was the chairman of Fairfax Media, deputy chairman of Prime Ag Australia, a director of the Reserve Bank of Australia and the US-based Wal-Mart Stores.

In October the then Halcygen said Mr Corbett would seek election to the board at the November annual general meeting (BD: Oct 14, 2010).

Mayne was up one cent or 1.1 percent to 91 cents.

## CLINUVEL PHARMACEUTICALS

Clinuvel says it has hosted its third 'Annual Scientific & Clinical Excellence Meeting' in Switzerland on January 23 and 24, 2010.

Clinuvel said the invitees and delegates were "global leaders and experts in photomedicine, dermatology and molecular biology" and met in Luzern to present and discuss the advances in their fields of expertise.

The company said the meeting was a forum reviewing the year's scientific and clinical advances in ultra-violet damage, malignant transformation and photo-protective therapies. Clinuvel is developing of Scenesse or afamelanotide for a range of light sensitivity indications along with CUV9900.

The company said the meeting focused on scientific and clinical advances in melanocortin 1 receptor signaling and other signaling pathways; melanogenesis and photoprotection; pigmentation and pigmentary disorders; ultraviolet radiation damage and its role on malignant transformation of skin; and clinical use of alpha-MSH analogues, including Clinuvel's drug Scenesse.

Clinuvel's chief scientific officer Dr Hank Agersborg said that "what started as a select panel of global experts in their specialties has now grown to an annual forum where heads of research institutes and academia meet to exchange in a structured fashion the current thinking in the fields of relevant science and clinical care".

"Usually, scientists and clinicians do not meet at open forums, and Clinuvel's objective of bringing together the world's prominent experts for mutual gain of knowledge is being fulfilled," Dr Agersborg said.

"Clinuvel's focus on photoprotection and malignant transformation seems to be much appreciated," Dr Agersborg said.

"We are not surprised by the growing interest in areas such as UV mutagenicity, dermal response and melanocortins, as these topics are most relevant to the public questions on causality of skin cancers," Dr Agersborg said.

The company said that "following the success of the meeting" it intended to host a satellite symposium on 'Advances in the science of skin and UV, and the role of melanocortins' during the 20th Congress of the European Association of Dermatology and Venereology in Lisbon, Portugal, scheduled for October 20 to 24, 2011.

Clinuvel was unchanged at \$2.21.